Read by QxMD icon Read


Eric S Molho, Mark Stacy, Patrick Gillard, David Charles, Charles H Adler, Joseph Jankovic, Marc Schwartz, Mitchell F Brin
BACKGROUND: Cervical dystonia is thought to result in high disease burden, but limited information exists on its impact on employment and work productivity. We utilized data from the Cervical Dystonia Patient Registry for the Observation of OnabotulinumtoxinA Efficacy ( identifier: NCT00836017) to assess the impact of cervical dystonia on employment and work productivity and examine the effect of onabotulinumtoxinA treatments on work productivity. METHODS: Subjects completed a questionnaire on employment status and work productivity at baseline and final visit...
March 2016: Movement Disorders Clinical Practice
Catherine S Hubbard, Lino Becerra, Jonathan H Smith, Justin M DeLange, Ryan M Smith, David F Black, Kirk M Welker, Rami Burstein, Fred M Cutrer, David Borsook
The aim of this study was to identify structural and functional brain changes that accompanied the transition from chronic (CM; ≥15 headache days/month) to episodic (EM; <15 headache days/month) migraine following prophylactic treatment with onabotulinumtoxinA (BoNT-A). Specifically, we examined whether CM patients responsive to prophylaxis (responders; n = 11), as evidenced by a reversal in disease status (defined by at least a 50% reduction in migraine frequency and <15 headache days/month), compared to CM patients whose migraine frequency remained unchanged (non-responders; n = 12), showed differences in cortical thickness using surface-based morphometry...
2016: Frontiers in Human Neuroscience
David A Ginsberg
No abstract text is available yet for this article.
October 11, 2016: Journal of Urology
Steven Siegel
No abstract text is available yet for this article.
October 11, 2016: Journal of Urology
L Arendt-Nielsen, G-L Jiang, R DeGryse, C C Turkel
OBJECTIVES: OnabotulinumtoxinA (onabotA) attenuates peripheral nociceptive transduction and consequently neuronal firing. The aim of this mechanistic study was to evaluate the effect of intra-articular (IA) onabotA in patients with painful knee osteoarthritis (OA). METHOD: We conducted a double-blind, randomized, placebo-controlled, 12-week trial using a single ultrasound-guided IA injection of onabotA (200 U). Patients (N = 121) were randomized to receive onabotA (n = 61) or placebo (n = 60)...
October 13, 2016: Scandinavian Journal of Rheumatology
Pawel Miotla, Rufus Cartwright, Katarzyna Skorupska, Michal Bogusiewicz, Ewa Markut-Miotla, Konrad Futyma, Tomasz Rechberger
AIMS: Urgency urinary incontinence (UUI), and the symptoms of overactive bladder (OAB) have a negative impact on female sexual function. The aim of this study was to investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on sexual function in women with OAB, using the multi domain Female Sexual Function Index (FSFI) questionnaire. METHODS: Sixty-eight sexually active women with idiopathic OAB with at least one episode of UUI and ≥8 micturitions per 24 h were recruited...
October 4, 2016: Neurourology and Urodynamics
Cindy L Amundsen, Holly E Richter, Shawn A Menefee, Yuko M Komesu, Lily A Arya, W Thomas Gregory, Deborah L Myers, Halina M Zyczynski, Sandip Vasavada, Tracy L Nolen, Dennis Wallace, Susan F Meikle
Importance: Women with refractory urgency urinary incontinence are treated with sacral neuromodulation and onabotulinumtoxinA with limited comparative information. Objective: To assess whether onabotulinumtoxinA is superior to sacral neuromodulation in controlling refractory episodes of urgency urinary incontinence. Design, Setting, and Participants: Multicenter open-label randomized trial (February 2012-January 2015) at 9 US medical centers involving 381 women with refractory urgency urinary incontinence...
October 4, 2016: JAMA: the Journal of the American Medical Association
Sheena Aurora, Rashmi Halker, Patricia Pozo-Rosich, Ronald DeGryse, Aubrey Manack Adams, Manjit Matharu
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Atul T Patel, Anthony B Ward, Carolyn Geis, Chengcheng Liu, Wolfgang H Jost, Rozalina Dimitrova
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Alberto Esquenazi, Khashayar Dashtipour, Abraham Alfaro, Ziyad Ayyoub, David Charles, Glenn D Graham, John R McGuire, Ib R Odderson, Atul T Patel, David M Simpson
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Alberto Esquenazi, Carolyn Geis, Theodore Wein, Anthony B Ward, Chengcheng Liu, Rozalina Dimitrova
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
Rungsima Wanitphakdeedecha, Chanida Ungaksornpairote, Arisa Kaewkes, Viboon Rojanavanich, Weeranut Phothong, Woraphong Manuskiatti
BACKGROUND: Botulinum toxin type A (BTA) has been approved for the treatment of strabismus, blepharospasm, muscle spasm, cervical dystonia, pain syndrome, glabella wrinkles, and severe primary axillary hyperhidrosis. Intradermal injection of BTA has been used off-label by many clinicians for the purpose of face-lifting effect. Few studies on onabotulinumtoxinA (ONA) demonstrated no clinical efficacy on face-lifting effect when comparing to normal saline solution (NSS). So far, there is no split-face comparison study on face-lifting effect of abobotulinumtoxinA (ABO)...
September 19, 2016: Journal of Cosmetic Dermatology
Catherine Copley-Merriman, Susan Zelt, Marci Clark, Ari Gnanasakthy
Although some symptoms of dermatologic diseases, such as pruritus and pain, can be subjectively assessed only by patients, the most commonly used endpoints in dermatology drug research traditionally have been clinician-reported outcomes. Research has found that patient-reported outcomes (PROs) were included in only one-quarter of 125 trials conducted between 1994 and 2001. Our objective was to characterize the impact of PROs in dermatology drug development from the patient, prescriber, regulator, payer, and manufacturer perspectives using a case study approach...
September 15, 2016: Patient
Lorenz Leitner, Ulla Sammer, Matthias Walter, Stephanie C Knüpfer, Marc P Schneider, Burkhardt Seifert, Jure Tornic, Ulrich Mehnert, Thomas M Kessler
Many of the patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity (NDO) present with chronic bacteriuria. In these patients, antibiotic prophylaxis has been widely recommended since bacteriuria might impair treatment efficacy and cause urinary tract infections (UTI) but the evidence is limited. The aim of this study was to evaluate if an antibiotic prophylaxis is needed in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections...
2016: Scientific Reports
Nathan Hoag, Sophie Plagakis, Samantha Pillay, Ailsa Wilson Edwards, Johan Gani
AIMS: Sacral neuromodulation (SNM) is a well-established treatment modality for refractory overactive bladder (OAB). There is a paucity of evidence examining the use of SNM in patients who have received prior intravesical onabotulinumtoxinA (BTXA) treatment. We aim to review those patients who underwent SNM for refractory OAB following treatment with BTXA. METHODS: A retrospective review was conducted to identify patients who had undergone prior intradetrusor BTXA for refractory OAB, then subsequent first-stage SNM...
September 9, 2016: Neurourology and Urodynamics
Stephanie C Knüpfer, Susanne A Schneider, Mareike M Averhoff, Carsten M Naumann, Günther Deuschl, Klaus-Peter Jünemann, Moritz F Hamann
BACKGROUND: To assess the efficacy and safety of intradetrusor onabotulinumtoxinA (OnabotA) injection treatment in patients with neurogenic lower urinary tract dysfunction (NLUTD), especially for patients with Parkinson disease (PD). METHODS: PD patients refractory to oral antimuscarinic participated in an off-label use study and were evaluated prior and after 200 IU OnabotA injection into detrusor muscle, including trigone. Changes due to treatment were evaluated using bladder diaries, urodynamics, and questionnaires...
2016: BMC Urology
Michele Poliziani, Marco Koch, Xierong Liu
BACKGROUND: The recommended reinjection interval for botulinum neurotoxin (BoNT) formulations in the treatment of cervical dystonia (CD) is generally ≥12 weeks, though intervals ≥10 weeks are approved for incobotulinumtoxinA in Europe. However, recurring symptoms can occur before the end of this period. Using qualitative research, we sought a greater understanding of disease burden, unmet patient needs, and barriers to treatment. METHODS: We conducted online semistructured, focus-group discussions, and online forum follow-up discussions among patients with CD, focusing on disease burden, patient needs, injection cycle preferences, and relationships with health care professionals...
2016: Patient Preference and Adherence
Gloria Tapias, Mar García-Romero, Carlos Crespo, Maribel Cuesta, Carles Forné, Samuel Ignacio Pascual-Pascual
OBJECTIVE: Cost-minimization analysis of onabotulinumtoxinA and abobotulinumtoxinA, taking into account the real dose administered to children with spasticity associated with dynamic equinus foot deformity due to cerebral palsy. METHOD: A single centre, observational, longitudinal, and retrospective study which included spastic paediatric patients aged 2-to-18-years and treated with onabotulinumtoxinA or abobotulinumtoxinA from December 1995 to October 2012, in the Paediatric Neurology Unit of a first-level Spanish hospital...
September 2016: Farmacia Hospitalaria
Donald Warren, Meghan Woody, Jennifer Vickers
Case 1 A 32-year-old woman was treated for the first time with onabotulinumtoxinA (BoNT), receiving 10 units in her forehead and 20 units in her glabella. She reported no history of skin disease and had a very active lifestyle. She first noticed blanching while doing a group workout and a friend inquired if she had "hives" on her forehead (Figure 1). She continued to note the blanching during workouts 5 months after injection. Each episode lasted 30 minutes to 2 hours. There were no associated symptoms with the blanching other than minor embarrassment...
2016: Skinmed
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"